{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mechlorethamine&page=16",
    "query": {
      "intervention": "Mechlorethamine",
      "page": 16
    },
    "page_size": 10
  },
  "pagination": {
    "page": 16,
    "page_size": 10,
    "total_count": 3019,
    "total_pages": 302,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mechlorethamine&page=17&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mechlorethamine&page=15&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T23:31:55.526Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07008378",
      "title": "A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "P-CD19CD20-ALLO1 Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-10-15",
      "completion_date": "2032-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • St Louis, Missouri • New Brunswick, New Jersey + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07008378"
    },
    {
      "nct_id": "NCT00002715",
      "title": "Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bleomycin sulfate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Stanford V regimen",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Mechlorethamine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Vinblastine",
          "type": "DRUG"
        },
        {
          "name": "Vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "1989-04",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002715"
    },
    {
      "nct_id": "NCT03885947",
      "title": "VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hematological Malignancy",
        "Acute Leukemia in Remission",
        "Acute Lymphoblastic Leukemia in Remission",
        "Myelodysplastic Syndromes",
        "Non-Hodgkin Lymphoma",
        "Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Cord blood stem cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cytoxan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        },
        {
          "name": "TBI",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Alla Keyzner",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 7,
      "start_date": "2019-02-21",
      "completion_date": "2021-03-10",
      "has_results": false,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03885947"
    },
    {
      "nct_id": "NCT00313235",
      "title": "Combined Modality Treatment for Patients With Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "DC Vaccine and Cyclophosphamide",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 41,
      "start_date": "2006-03",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-13",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313235"
    },
    {
      "nct_id": "NCT00630032",
      "title": "Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "epirubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNICANCER",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 762,
      "start_date": "2007-09",
      "completion_date": "2020-09-03",
      "has_results": true,
      "last_update_posted_date": "2024-02-21",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 17,
      "location_summary": "Scottsdale, Arizona • Denver, Colorado • Jacksonville, Florida + 14 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00630032"
    },
    {
      "nct_id": "NCT05878184",
      "title": "Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "SC291",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sana Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 16,
      "start_date": "2023-05-02",
      "completion_date": "2038-11-04",
      "has_results": false,
      "last_update_posted_date": "2025-10-02",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Palo Alto, California • Atlanta, Georgia + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05878184"
    },
    {
      "nct_id": "NCT00493649",
      "title": "Adj TC + Herceptin Early Stage Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Taxotere",
          "type": "DRUG"
        },
        {
          "name": "Cytoxan",
          "type": "DRUG"
        },
        {
          "name": "Herceptin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Oncology Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 493,
      "start_date": "2007-06",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2016-11-03",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 69,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00493649"
    },
    {
      "nct_id": "NCT01660750",
      "title": "A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "Carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Criterium, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2013-01",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2017-10-18",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Palm Springs, California • Worcester, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01660750"
    },
    {
      "nct_id": "NCT05869955",
      "title": "A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Idiopathic Inflammatory Myopathy",
        "Systemic Sclerosis",
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CC-97540",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 270,
      "start_date": "2023-09-13",
      "completion_date": "2028-08-29",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 25,
      "location_summary": "Aurora, Colorado • Denver, Colorado • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05869955"
    },
    {
      "nct_id": "NCT00004132",
      "title": "Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Drug/Agent Toxicity by Tissue/Organ",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Oral Complications",
        "Radiation Toxicity"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "palifermin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-01",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2013-06-26",
      "last_synced_at": "2026-11-02T23:31:55.526Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004132"
    }
  ]
}